trial

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

NCTId NCT00176436
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 40 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2008-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2004-02
Primary completion
2008-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Diet support groupGroup counseling and exercise

Sponsors

University of Maryland, Baltimore CountyLead Sponsor
Eli Lilly and CompanyCollaborator

Investigators

1
M Patricia Ball, R.N.,C.,M.S.Principal Investigator

Sites

1 total
Catonsville, United States

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE4
Primary Completion Date
2008-03
Status
COMPLETED
relationships
The graph out of here
drug
Diet support group
drug
Group counseling and exercise
drug
lead_sponsor
University of Maryland, Baltimore County
company
collaborator
Eli Lilly and Company
company
indication
Schizophrenia
indication
Weight Loss
indication
Motor Activity
indication
investigator
M Patricia Ball, R.N.,C.,M.S.
person